1-Minute Pearls/Pitfalls for the Clinician

Area of Science:

• Hepatology
• Endocrinology
• Metabolic Diseases

Background:

• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes mellitus (T2DM) and obesity.
• These conditions increase the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and advanced liver fibrosis.
• Current guidelines recommend fibrosis risk stratification, but implementation is inconsistent.

Purpose of the Study:

• To emphasize the critical need for integrating noninvasive fibrosis assessment into routine metabolic care pathways.
• To advocate for early detection and timely referral of patients with or at risk of MASLD and advanced fibrosis.
• To improve long-term liver outcomes in patients receiving GLP-1 RAs.

Main Methods:

• This study is a review and expert opinion piece.
• It analyzes current practices in metabolic care and fibrosis assessment.
• It highlights discrepancies between guideline recommendations and clinical implementation.

Main Results:

• Noninvasive fibrosis risk stratification is underutilized in patients with T2DM and obesity.
• Inconsistent implementation leads to delayed diagnosis of cirrhosis and its complications.
• There is a significant gap between recommended and actual clinical practice.

Conclusions:

• Integrating routine fibrosis assessment into metabolic care is essential.
• Early detection and management can prevent advanced liver disease progression.
• Optimizing care pathways will improve patient outcomes and reduce liver-related morbidity.